TITLE

The L-dopa response in vascular parkinsonism

AUTHOR(S)
Zijlmans J C M; Katzenschlager R; Daniel S E; Lees A J L
PUB. DATE
April 2004
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Apr2004, Vol. 75 Issue 4, p545
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To determine whether a positive L-dopa response in vascular parkinsonism (VP) is correlated with the presence of nigrostriatal pathology due to either vascular damage or neuronal cell loss. METHODS: Seventeen patients with pathologically confirmed VP were selected from the pathological collection of the Queen Square Brain Bank for Neurological Disorders, and their L-dopa response during life was compared with the presence of macroscopic vascular damage in the nigrostriatal pathway and microscopic substantia nigra cell loss. RESULTS: Ten of the twelve patients with a good or excellent response had macroscopic infarcts or lacunae caused by enlarged perivascular spaces in the basal ganglia or microscopic neuronal cell loss in the substantia nigra. In contrast, only one of the five patients with a moderate or no response had lacunae in the putamen, and none had lacunar infarcts or substantia nigra cell loss. CONCLUSION: These results suggest that a substantial number of patients with clinically suspected VP may respond with benefit to dopaminergic therapy, especially those with lesions in or close to the nigrostriatal pathway.
ACCESSION #
44658922

 

Related Articles

  • Extrastriatal dopamine D2 receptors in Parkinson's disease: a longitudinal study. Kaasinen, V.; Aalto, S.; NÅgren, K.; Hietala, J.; Sonninen, P.; Rinne, J. O. // Journal of Neural Transmission;Jun2003, Vol. 110 Issue 6, p591 

    Summary. Most antiparkinsonian drugs are known to act through central dopamine D2 receptor agonism. A previous longitudinal positron emission tomography (PET) study has indicated that, in the striatum of Parkinson's disease (PD) patients, dopamine D2 receptor binding declines at a relatively...

  • Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease. Müller, Th.; Benz, S.; Börnke, C.; Russ, H.; Przuntek, H. // Journal of Neural Transmission;Jun2003, Vol. 110 Issue 6, p603 

    Summary. Clinicians use acute challenges with levodopa (LD) and/or apomorphine (A) for diagnostic dopaminergic response tests in Parkinson's disease (PD) patients. We consecutively compared the value of both drugs with performance of repeated ratings and adverse effect recording. Oral...

  • Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson’s patients. Stocchi, F.; Barbato, L.; Nordera, G.; Bolner, A.; Caraceni, T. // Journal of Neural Transmission;Feb2004, Vol. 111 Issue 2, p173 

    Summary. The aim of this trial was to evaluate the effects of the COMT inhibitor entacapone on both the pharmacokinetic profile and clinical efficacy of controlled release levodopa in Parkinson’s disease (PD) patients. Twelve PD patients experiencing ‘end-of-dose’ type motor...

  • Intact encoding, impaired consolidation in procedural learning in Parkinson’s disease. Cohen, Henri; Pourcher, Emmanuelle // Experimental Brain Research;May2007, Vol. 179 Issue 4, p703 

    Idiopathic Parkinson’s disease (IPD) patients and matched healthy participants were compared on a non-motor procedural task involving semantically related inverted word pairs, and 3 months later to determine the extent of skill consolidation. IPD patients were found to acquire new...

  • Interval timing and Parkinson’s disease: heterogeneity in temporal performance. Merchant, Hugo; Luciana, Monica; Hooper, Catalina; Majestic, Stacy; Tuite, Paul // Experimental Brain Research;Jan2008, Vol. 184 Issue 2, p233 

    Interval timing deficiencies in Parkinson’s disease (PD) patients have been a matter of debate. Here we test the possibility of PD heterogeneity as a source for this discrepancy. Temporal performance of PD patients and control subjects was assessed during two interval tapping tasks and...

  • Cell death in Parkinson's disease. Maruyama, Wakako; Naoi, Makoto // Journal of Neurology;Sep2002 Supplement 2, Vol. 249, pii06 

    The cause of neuronal cell death in Parkinson's disease is still an enigma. However, recent results obtained by analyses of postmortem brain suggest that a mitochondria-dependent apoptotic signal was activated. The involvement of dopamine-derived endogenous neurotoxin in the pathogenesis of PD...

  • Dopamine-Independent Locomotor Actions of Amphetamines in a Novel Acute Mouse Model of Parkinson Disease. Sotnikova, Tatyana D.; Beaulieu, Jean-Martin; Barak, Larry S.; Wetsel, William C.; Caron, Marc G.; Gainetdinov, Raul R. // PLoS Biology;Aug2005, Vol. 3 Issue 8, p1488 

    Brain dopamine is critically involved in movement control, and its deficiency is the primary cause of motor symptoms in Parkinson disease. Here we report development of an animal model of acute severe dopamine deficiency by using mice lacking the dopamine transporter. In the absence of...

  • Initiation of symptomatic therapy in Parkinson's disease: dopamine agonists versus levodopa. Lev, Nirit; Djaldetti, Ruth; Melamed, Eldad // Journal of Neurology;Sep2007, Vol. 254 Issue S5, p19 

    Parkinson's disease (PD) is a chronic progressive neurodegenerative disease and its early treatment is of prime importance. Early treatment of PD has several goals: to increase the patient's quality of life and to have symptomatic benefits, to slow disease progression, and to prevent...

  • Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes? Annie Lannuzel; G. U. Höglinger; S. Verhaeghe; L. Gire; S. Belson; M. Escobar-Khondiker; P. Poullain; W. H. Oertel; E. C. Hirsch; B. Dubois; M. Ruberg // Brain: A Journal of Neurology;Mar2007, Vol. 130 Issue 3, p816 

    In Guadeloupe, there is an abnormally high frequency of atypical parkinsonism. Only one-third of the patients that develop parkinsonian symptoms were reported to present the classical features of idiopathic Parkinson disease and one-third a syndrome resembling progressive supranuclear palsy...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics